|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||50.70 - 50.70|
|52-week range||50.65 - 81.03|
|Beta (5Y monthly)||0.06|
|PE ratio (TTM)||44.47|
|Forward dividend & yield||1.18 (2.32%)|
|Ex-dividend date||28 Mar 2024|
|1y target est||79.95|
An Alzheimer's drug in injectable form could be the key for Biogen, Eisai to ease pressures and concerns of a limited market and revenue.
Japanese pharma company Eisai (ESAIY) reported positive results in clinical trials of its Alzheimer’s drug Leqembi. This could mean a revolution for administering the drug, which is currently only administered via IV. Yahoo Finance’s Anjalee Khemlani breaks down what this means in terms of access and costs as concerns about side effects and formularies are evident. Pfizer (PFE) and BioNTech (BNTX) are also working together to develop a combo COVID-flu vaccine, showing positive data in its trial. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 "Lecanemab for Early Alzheimer's Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials